Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Perseus ProteomicsTSE:4882 +2.56%56 Current Ratio is 24.58 as of Mar. 2026, which is 9% above its 10-year median of 22.63. GuruFocus rates TSE:4882 with a GF Score™ of 56/100 and a GF Value™ of 円439.72 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,000 Drug Manufacturers companies, Perseus Proteomics ranks better than 98.3% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Perseus Proteomics's current ratio for the quarter that ended in Mar. 2026 was 24.58.
Perseus Proteomics has a current ratio of 24.58. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Perseus Proteomics's Current Ratio or its related term are showing as below:
TSE:4882'
s Current Ratio Range Over the Past 10 Years
Min: 8.68 Med: 22.63 Max: 61.98
Current: 24.58
During the past 9 years, Perseus Proteomics's highest Current Ratio was 61.98. The lowest was 8.68. And the median was 22.63.
TSE:4882's Current Ratio is ranked better than 98.3% of 1000
companies
in the Drug Manufacturers industry
Industry Median: 2
vs TSE:4882: 24.58
Perseus Proteomics (TSE:4882) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Perseus Proteomics Current Ratio Related Terms
Perseus Proteomics Current Ratio Historical Data
* Premium members only.
The historical data trend for Perseus Proteomics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4882 vs LLY, JNJ, ABBV: Current Ratio Comparison
For the Drug Manufacturers - General subindustry, Perseus Proteomics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perseus Proteomics Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Perseus Proteomics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Perseus Proteomics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perseus Proteomics (TSE:4882) has a Current Ratio of 24.58 as of Mar. 2026. This is near median its historical median of 22.63. Over the past decade, Perseus Proteomics' Current Ratio has ranged from 8.68 to 61.98. According to the industry distribution chart, Perseus Proteomics ranks #17 out of 1000 companies in the Drug Manufacturers industry, placing it in the top 1.7%.
Is Perseus Proteomics' Current Ratio too high?
Perseus Proteomics' current Current Ratio of 24.58 is near median its 10-year median of 22.63. Over the past 10 years, this metric has ranged from a low of 8.68 to a high of 61.98. The Drug Manufacturers industry median Current Ratio is 2.00. Perseus Proteomics' value of 24.58 is 1129% above this industry median. Based on the distribution chart, Perseus Proteomics ranks #17 out of 1000 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Perseus Proteomics has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Perseus Proteomics' Current Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Perseus Proteomics ranks #17 out of 1000 companies for Current Ratio. This places Perseus Proteomics in the top 2% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.00. Perseus Proteomics' value of 24.58 is 1129% above this benchmark. Historically, Perseus Proteomics' own Current Ratio has ranged from 8.68 to 61.98 over the past decade. While the company's 10-year median is 22.63 vs. the industry median of 2.00, Perseus Proteomics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 1,000 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Perseus Proteomics's current Current Ratio of 24.58 is 1129% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perseus Proteomics's current Current Ratio is 24.58, which is near median its own 10-year median of 22.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perseus Proteomics stock overvalued right now?
Based on GuruFocus' analysis, Perseus Proteomics (TSE:4882) is currently considered Significantly Undervalued. The stock's GF Value™ is 円439.72, compared to a current price of 円160.00 — trading 63.6% below its estimated fair value. The current Current Ratio is 24.58, which is near median its 10-year median of 22.63 and 1129% above the Drug Manufacturers industry median of 2.00. Perseus Proteomics' overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Perseus Proteomics (TSE:4882), the current Current Ratio is 24.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perseus Proteomics (TSE:4882) Overvalued in 2026?
Based on GuruFocus' analysis, Perseus Proteomics stock appears to be undervalued.
The current stock price of 円160.00 is trading 63.6% below its estimated GF Value™ of 円439.72.
GuruFocus considers Perseus Proteomics to be Significantly Undervalued.
Key valuation signals for TSE:4882:
Current Ratio: 24.58 (near median its 10-year median of 22.63)
GF Value™: 円439.72 vs. price of 円160.00 (63.6% below fair value)
Industry Position: 1129% above the Drug Manufacturers median (#17 of 1000)
No single metric tells the full story. See the TSE:4882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody-based therapeutics and diagnostic drugs to cure cancer and other diseases. The Company operates in a single segment, the pharmaceutical business.
56GF Score
Get the complete analysis for TSE:4882
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4882 has been successfully added to your 
